Clear All
11765 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
67457-0246-01 67457-0246 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Apr 1, 2011 In Use
55648-0632-01 55648-0632 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
55648-0635-02 55648-0635 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
00480-9262-08 00480-9262 Octreotide Acetate Octreotide Acetate 3.33 mg/ml Hormonal Therapy Somatostatin Analog Intramuscular Oct 1, 2024 In Use
55390-0160-10 55390-0160 Octreotide Acetate Octreotide Acetate Hormonal Therapy Somatostatin Analog Apr 4, 2005 Feb 28, 2013 No Longer Used
67457-0246-00 67457-0246 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Apr 12, 2013 In Use
64679-0634-01 64679-0634 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
25021-0452-01 25021-0452 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec 15, 2013 Jan 31, 2023 In Use
55648-0636-01 55648-0636 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous May 11, 2011 In Use
62756-0352-40 62756-0352 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Aug 14, 2007 Jan 31, 2017 No Longer Used
50242-0070-86 50242-0070 Obinutuzumab Gazyva 1000.0 mg/40mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov 4, 2013 In Use
50242-0070-01 50242-0070 Obinutuzumab Gazyva 1000.0 mg/40mL Immunotherapy Monoclonal Antibody CD20 Intravenous Nov 1, 2013 In Use
83047-0410-04 83047-0410 Obecabtagene autoleucel AUCATZYL 10000000.0 /1, 100000000.0 /1, 300000000.0 /1 Immunotherapy CAR-T CD19 Intravenous Nov 8, 2024 In Use
81481-0803-01 81481-0803 Nogapendekin alfa inbakicept-pmln ANKTIVA 400.0 ug/.4mL Immunotherapy Cytokine IL-15 (⍺,β,ɣ) Intravesical May 6, 2024 In Use
00003-3734-13 00003-3734 Nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 8, 2017 In Use
00003-3756-14 00003-3756 nivolumab OPDIVO 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Aug 30, 2021 In Use
00003-3772-11 00003-3772 Nivolumab Opdivo 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 22, 2014 In Use
00003-3774-12 00003-3774 Nivolumab Opdivo 10.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Dec 22, 2014 In Use
00003-7125-11 00003-7125 nivolumab and relatlimab-rmbw OPDUALAG 12.0 mg/mL, 4.0 mg/mL Immunotherapy Checkpoint Inhibitor, Monoclonal Antibody PD-1, LAG3 Intravenous Mar 18, 2022 In Use
00003-6120-01 00003-6120 Nivolumab and hyaluronidase-nvhy OPDIVO QVANTIG 2000.0 U/mL, 120.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Subcutaneous Jan 2, 2025 In Use
82448-0100-14 82448-0100 Nirogacestat OGSIVEO 100.0 mg/1 Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Oral Nov 27, 2023 In Use
82448-0050-18 82448-0050 Nirogacestat OGSIVEO 50.0 mg/1 Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Oral Nov 27, 2023 In Use
82448-0150-14 82448-0150 Nirogacestat OGSIVEO 150.0 mg/1 Ancillary Therapy Miscellaneous Agent Ɣ Secretase Inhibitor Oral Nov 27, 2023 In Use
00173-0912-61 00173-0912 Niraparib ZEJULA 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jun 27, 2023 In Use
00173-0909-13 00173-0909 Niraparib ZEJULA 100.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Jun 27, 2023 In Use

Found 11765 results — Export these results